Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Biomea Fusion, Inc. (BMEA : NSDQ)
 
 • Company Description   
Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California.

Number of Employees: 106

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.86 Daily Weekly Monthly
20 Day Moving Average: 2,109,571 shares
Shares Outstanding: 37.57 (millions)
Market Capitalization: $69.88 (millions)
Beta: -0.13
52 Week High: $13.07
52 Week Low: $1.29
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -26.48% -28.69%
12 Week 7.51% -6.80%
Year To Date -52.06% -54.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
900 MIDDLEFIELD ROAD 4TH FLOOR
-
REDWOOD CITY,CA 94063
USA
ph: 650-980-9099
fax: -
ir@biomeafusion.com http://www.biomeafusion.com
 
 • General Corporate Information   
Officers
Michael J.M. Hitchcock - Interim Chief Executive Officer; Director
Rainer Erdtmann - Chief Operating Officer; Director
Eric Aguiar - Director
Bihua Chen - Director
Sumita Ray - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09077A106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
Share - Related Items
Shares Outstanding: 37.57
Most Recent Split Date: (:1)
Beta: -0.13
Market Capitalization: $69.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.35 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/30/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.43
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 26.61%
vs. Previous Quarter: 1.23%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -197.71
12/31/24 - -150.95
ROA
06/30/25 - -
03/31/25 - -134.84
12/31/24 - -111.86
Current Ratio
06/30/25 - -
03/31/25 - 2.25
12/31/24 - 3.15
Quick Ratio
06/30/25 - -
03/31/25 - 2.25
12/31/24 - 3.15
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.76
12/31/24 - 1.42
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©